RB growth control evasion in lung cancer

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2371-2374

  Caputi, Mario ^a   Esposito, Vincenzo ^a,b   Groger, Angela M ^b,c   De Luca, Antonio ^b   Pacilio, Carmen ^b   Dekan, Gerhard ^c   Giordano, Giovan G ^a   Baldi, Feliciano ^a   Wolner, Ernst ^c   Giordano, Antonio ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cyclin D1; Lung cancer; p16; Rb

Indexed keywords

CYCLIN D1; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER GROWTH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM STAGING; RETINOBLASTOMA PROTEIN;

EID: 15144353018     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boring CC, Squires TS, and Tong T: Cancer Statistics. Cancer J Clin 43: 7-26, 1993.
2. Mountain CF: A new international staging system for lung cancer. Chest 89: 225-233, 1986.
3. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
4. Sang N, Baldi A, Giordano A: The roles of tumor suppressors pRb and pS3 in cell proliferation and cancer. Mol and Cell Differ 3: 1-29, 1995.
5. Chellapan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR: The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053-1061, 1991.
6. Hiebert SW, Chellapan SP, Horowitz JM, Nevins JR: The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 6: 177-185, 1992.
7. Chen PL, Scully P, Shew JY, Wang JYJ, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58: 1193-1198, 1989.
8. De Caprio JA, Furukawa Y, Ajchenbaum F, Griffin JD, Livingston DM: The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad USA 89: 1795-1798, 1992.
9. De Caprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM: SV40 Large Tumor Antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54: 275-283, 1988.
10. Dyson N, Howley PM, Muenger K, Harlow E: The human Papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937, 1989.
11. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E: Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124-129, 1988.
12. Levin WJ, Casey G, Ramos JC, Arboleda MJ, Reissmann PT, Slamon DJ: Tumor suppressor and immediate early transcription factor genes in non small cell lung cancer. Chest 106: 372s-375s, 1994.
13. Higashiyama M, Doi Ȯ, Kodama K, Yokouchi, Tateishi R: Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 51: 544-551, 1994.
14. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF: Altered retinoblastoma protein expression and prognosis in early stage non small cell lung carcinoma. J Natl Cancer Inst 86: 695-99, 1994
15. Serrano M, Hanno GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
16. Ink4. Cancer Res 54: 5816-5820, 1994.
17. Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product. Cancer Res 54: 6078-6082, 1994.
18. INK4/MTS1 tumor suppressor gene product. EMBO J 14: 503-511, 1995.
19. Cordon-Carlo C: Mutation of Cell Cycle Regulators. Am J Pathol 147: 1-16, 1995.
20. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, Arnold A: PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sei USA 88: 9638-9642, 1991.
21. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, DeFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133, 1993.
22. DeBoer CJ, Loyson S, Kluin PM, Kluin-Nelemans HC, Schuring E, Van Krieken JHJM: Multiple breakpoints within the Bcl-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res 53: 4148-4152, 1993.
23. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90: 9026-9030, 1993.
24. Leach FS, Elledge SJ, Sherr CJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B: Amplification of cyclin genes in colorectal cancer. Cancer Res 53: 1986-1989, 1993.
25. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 796: 1010-1016, 1993.
26. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WDJ, Cerny T, Thatcher N: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small cell lung cancer. Br J Cancer 73: 294-300, 1 996.
27. Kamb A, Gruis NA, Weaver-Feldhaus J, Lie Q, Harshman K, Tavtigian SV, Stocken E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1 994.
28. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma: Cancer Res 54: 3396-3397, 1994.
29. INk4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378, 1994.
30. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Felhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10: 1061-1067, 1995.
31. Caputi M, Esposito V, Groeger AM, De Luca A, Dean C, Pacilio C, Mueller MR, Giordano GG, Baldi F, Wolner E, Giordano A: Prognostic role of cyclin D1 in lung cancer: relationship with PCNA. (submitted)
32. Groeger AM, Caputi M, Esposito V, De Luca A, Bagella L, Pacilio C, Mueller MR, Giordano GG, Baldi F, Kaiser HE, Wolner E, Giordano A: Independent prognostic role of p16 expression in lung cancer. (submitted)
33. World Health Organization: Histological typing of lung tumors. 2nd ed., Geneva 25-26, 1981. Oncogene 8: 1913-1919, 1993.
34. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ: Lung. Manual for staging of cancer. 4th ed., Chicago, American Joint Committee, on Cancer 115-122, 1992.
35. Baldi A, Esposito V, De Luca A, Howard CM, Mazzarella G, Baldi F, Caputi M, Giordano A: Differential expression of the retinoblastoma gene family members Rb/p 105, p107, and Rb2/p 130 in lung cancer. Clin Cancer Res 2: 1239-1245, 1996.
36. Esposito V, De Luca A, Baldi A, D'Aponte A, Cavallotti I, Meoli I, Baldi F, Caputi M, Giordano A: Altered expression of pS3 and Rb tumor suppressor genes in lung cancer: Relationship with survival. Int J Oncol 9: 439-443, 1996.
37. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, Nagatake M, Sugiura T, Ariyoshi Y, Mitsudomi T, Takahashi T: Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancer. Clin Cancer Res 3: 1051-1058, 1997.